Experienced in Bipolar Disorder (BPD)

Dr. Marc E. Agronin

Psychiatry | Geriatrics
Miami Jewish Health Systems Inc
5200 Ne 2nd Ave, 
Miami, FL 
Accepting New Patients
Offers Telehealth
Experienced in Bipolar Disorder (BPD)
Miami Jewish Health Systems Inc
5200 Ne 2nd Ave, 
Miami, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Marc Agronin is a Psychiatrist and a Geriatrics provider in Miami, Florida. Dr. Agronin is rated as an Experienced provider by MediFind in the treatment of Bipolar Disorder (BPD). His top areas of expertise are Alzheimer's Disease, Dementia, Cerebellar Degeneration, and Lewy Body Dementia (LBD). Dr. Agronin is currently accepting new patients.

His clinical research consists of co-authoring 25 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Psychiatry
Geriatrics
Licenses
Psychiatry & Neurology in FL
Hospital Affiliations
Douglas Gardens Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

MIAMI JEWISH HEALTH SYSTEMS INC
5200 Ne 2nd Ave, Miami, FL 33137

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

Long-Term Nicotine Treatment of Mild Cognitive Impairment
Long-Term Nicotine Treatment of Mild Cognitive Impairment
Enrollment Status: Completed
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Nicotine Transdermal Patch
Study Phase: Phase 2
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 22, 2025
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
Donanemab Follow-On Study: Safety, Tolerability, And Efficacy in Symptomatic Alzheimer's Disease With Validation of Remote Neuropsychological Assessments
Donanemab Follow-On Study: Safety, Tolerability, And Efficacy in Symptomatic Alzheimer's Disease With Validation of Remote Neuropsychological Assessments
Enrollment Status: Completed
Publish Date: June 13, 2025
Intervention Type: Drug, Other
Study Drug: Donanemab
Study Phase: Phase 2
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
Enrollment Status: Completed
Publish Date: May 16, 2025
Intervention Type: Drug
Study Drug: ALZ-801
Study Phase: Phase 3
Pilot Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease
Pilot Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease
Enrollment Status: Completed
Publish Date: May 09, 2025
Intervention Type: Drug
Study Drug: Dronabinol
Study Phase: Phase 2
Escitalopram for Agitation in Alzheimer's Disease
Escitalopram for Agitation in Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Escitalopram
Study Phase: Phase 3
Longitudinal Cohort Study of Resource Use and Cost of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in the United States (GERAS-US)
Longitudinal Cohort Study of Resource Use and Cost of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in the United States (GERAS-US)
Enrollment Status: Active_not_recruiting
Publish Date: October 24, 2024
Intervention Type: Drug
A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Three Dose Strengths of T3D-959 in Subjects With Mild-to-Moderate Alzheimer's Disease
A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Three Dose Strengths of T3D-959 in Subjects With Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: July 19, 2024
Intervention Type: Drug
Study Drug: T3D-959
Study Phase: Phase 2
A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AGB101on Slowing Progression of Mild Cognitive Impairment Due to Alzheimer's Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AGB101on Slowing Progression of Mild Cognitive Impairment Due to Alzheimer's Disease
Enrollment Status: Completed
Publish Date: May 17, 2024
Intervention Type: Drug
Study Drug: AGB101
Study Phase: Phase 2/Phase 3
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: October 13, 2022
Intervention Type: Drug
Study Drug: LY3002813
Study Phase: Phase 2
A Phase, I Prospective, Randomized, Double-Blinded, Placebo-controlled, Trial to Evaluate the Safety and Potential Efficacy of Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease
A Phase, I Prospective, Randomized, Double-Blinded, Placebo-controlled, Trial to Evaluate the Safety and Potential Efficacy of Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease
Enrollment Status: Completed
Publish Date: December 14, 2021
Intervention Type: Biological
Study Drug: Longeveron Mesenchymal Stem Cells
Study Phase: Phase 1
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Enrollment Status: Completed
Publish Date: October 01, 2020
Intervention Type: Other, Drug
Study Phase: Phase 2
A Clinico-Pathological Study of the Correspondence Between 18F-AV-1451 PET Imaging and Post-Mortem Assessment of Tau Pathology
A Clinico-Pathological Study of the Correspondence Between 18F-AV-1451 PET Imaging and Post-Mortem Assessment of Tau Pathology
Enrollment Status: Completed
Publish Date: September 07, 2020
Intervention Type: Drug, Procedure
Study Phase: Phase 3
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: October 10, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 16 Less Clinical Trials

25 Total Publications

Cognitive Impairment Is Associated with Alterations in Diet Quality and Inflammatory Biomarkers in Older Adults: A Cross-Sectional Analysis of Data Collected from the Microbiome in Aging Gut and Brain (MiaGB) Consortium Cohort.
Cognitive Impairment Is Associated with Alterations in Diet Quality and Inflammatory Biomarkers in Older Adults: A Cross-Sectional Analysis of Data Collected from the Microbiome in Aging Gut and Brain (MiaGB) Consortium Cohort.
Journal: The Journal of nutrition
Published: March 19, 2025
Similar Doctors
Distinguished in Bipolar Disorder (BPD)
Dr. Nelson E. Cordero-Torres
Psychiatry | Child and Adolescent Psychiatry
Distinguished in Bipolar Disorder (BPD)
Dr. Nelson E. Cordero-Torres
Psychiatry | Child and Adolescent Psychiatry

Ventre Medical Associates LLC

7369 Sheridan St, Suite 101, 
Hollywood, FL 
 (14.7 miles away)
954-561-6222
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Nelson Cordero-Torres is a Psychiatrist and a Child and Adolescent Psychiatrist in Hollywood, Florida. Dr. Cordero-Torres is rated as an Advanced provider by MediFind in the treatment of Bipolar Disorder (BPD). His top areas of expertise are Bipolar Disorder (BPD), Schizophrenia, Schizoaffective Disorder, and Major Depression. Dr. Cordero-Torres is currently accepting new patients.

Distinguished in Bipolar Disorder (BPD)
Dr. Sohail S. Punjwani
Psychiatry | Child and Adolescent Psychiatry
Distinguished in Bipolar Disorder (BPD)
Dr. Sohail S. Punjwani
Psychiatry | Child and Adolescent Psychiatry

Compass Health Systems PA

7481 W Oakland Park Blvd, Suite 100, 
Tamarac, FL 
 (24.0 miles away)
888-852-6672
Languages Spoken:
English, Hindi, Urdu
See accepted insurances
Accepting New Patients

Sohail Punjwani is a Psychiatrist and a Child and Adolescent Psychiatrist in Tamarac, Florida. Dr. Punjwani is rated as a Distinguished provider by MediFind in the treatment of Bipolar Disorder (BPD). His top areas of expertise are Major Depression, Seasonal Affective Disorder (SAD), Bipolar Disorder (BPD), and Generalized Anxiety Disorder (GAD). Dr. Punjwani is currently accepting new patients.

Distinguished in Bipolar Disorder (BPD)
Dr. Patrick Pinchinat
Psychiatry | Addiction Medicine
Distinguished in Bipolar Disorder (BPD)
Dr. Patrick Pinchinat
Psychiatry | Addiction Medicine
18503 Pines Blvd, Suite 215, 
Pembroke Pines, FL 
 (18.1 miles away)
954-392-6099
Languages Spoken:
English, French, Haitian, Haitian Creole
See accepted insurances
Accepting New Patients
Offers Telehealth

Patrick Pinchinat is a Psychiatrist and an Addiction Medicine provider in Pembroke Pines, Florida. Dr. Pinchinat is rated as a Distinguished provider by MediFind in the treatment of Bipolar Disorder (BPD). His top areas of expertise are Schizophrenia, Schizoaffective Disorder, Major Depression, and Bipolar Disorder (BPD). Dr. Pinchinat is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Agronin's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile